LB-05PHASE III TRIAL EXPLORING THE COMBINATION OF BEVACIZUMAB AND LOMUSTINE IN PATIENTS WITH FIRST RECURRENCE OF A GLIOBLASTOMA: THE EORTC 26101 TRIAL
Wolfgang Wick(German Cancer Research Center), Martin J. van den Bent(Erasmus MC Cancer Institute), Michael Weller(University Hospital of Zurich), Martin Bendszus(Heidelberg University), Walter Taal(Heidelberg University), Thierry Gorlia(European Organisation for Research and Treatment of Cancer), Julien Dômont(Heidelberg University), Roger Stupp(Northwestern University), Martin Taphoorn(Leiden University Medical Center), Felix Sahm(German Cancer Research Center), Michael Platten(German Cancer Research Center), Mario Campone(Institut de Cancérologie de l'Ouest), Davide Musmeci(European Organisation for Research and Treatment of Cancer), Michel Fabbro(Nordic Society of Gynecologic Oncology), Ahmed Idbaïh(Centre National de la Recherche Scientifique), Aa Brandes(University of Modena and Reggio Emilia), V. Golfinopoulos(Universitat de València), Paul M. Clément(Universitair Ziekenhuis Leuven), F Dubois(Universidade Federal de Minas Gerais), Carlos Bais(Eos Neuroscience (United States))
Cited by 79
Related Papers
<i>MGMT</i> Gene Silencing and Benefit from Temozolomide in Glioblastoma
|New England Journal of Medicine|2005|7.2k
Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer
|New England Journal of Medicine|2016|2.5k
EANO guidelines on the diagnosis and treatment of diffuse gliomas of adulthood
|Nature Reviews Clinical Oncology|2020|1.9k